IL4I1 是一个代谢免疫检查点,激活AHR并促进瘤的进展
Ahmed Sadik1, Luis F Somarribas Patterson2, Selcen Öztürk3
1DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Faculty of Bioscience, Heidelberg University, 69120 Heidelberg, Germany.
Cell
|August 21, 2020
概括
激活阿里尔碳化合物受体 (AHR),促进癌症的进展和免疫抑制. 阻断IL4I1是一种有前途的新癌症治疗策略.
科学领域:
- 免疫学
- 癌症学
- 生物化学
背景情况:
- 通过酸催化剂激活酸受体 (AHR),促进瘤恶性并抑制抗瘤免疫力.
- AHR目标基因的特定环境阻碍了对人类癌症的AHR活性进行全面研究.
研究的目的:
- 在各种人类癌症中识别与AHR活性相关的新酶.
- 研究IL4I1在癌症进展和免疫逃避中的作用.
- 探索IL4I1作为癌症治疗中的潜在治疗点.
主要方法:
- 自然语言处理以获得全组织AHR签名.
- 与IDO1和TDO2相比,IL4I1与AHR活动的相关性分析
- 使用慢性淋巴细胞白血病 (CLL) 的小鼠模型进行体内研究.
- 评估IL4I1对患者生存和免疫反应的影响.
主要成果:
- 在32种瘤类型中,IL4I1被确定为常见的AHR活动标志物,超过IDO1和TDO2.
- 在质瘤患者中,IL4I1通过醇代谢物和氨酸激活AHR,与生存率的降低相关.
- 在小鼠中,IL4I1促进癌细胞运动,抑制适应性免疫力,恶化CLL的进展.
- 免疫检查点阻塞 (ICB) 诱导了IDO1和IL4I1,这表明IL4I1可能解释了ICB和IDO1联合抑制疗法的有限疗效.
结论:
- IL4I1 是由AHR驱动的瘤恶性和免疫抑制的显著调解者.
- 阻断IL4I1是一种新且有前途的治疗策略.
- 了解IL4I1的作用对于改善癌症免疫治疗结果至关重要.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
5.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.0K
T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
lncRNA - Long Non-coding RNAs
9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The JAK-STAT Signaling Pathway
11.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.2K


